Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Prothena (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on protein dysregulation expertise, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 20, 2025, after U.S. market close. The company will host a live audio conference call at 4:30 PM ET on the same day.
The conference call will be accessible through the company's website at www.prothena.com under the Investors tab, with a replay available for at least 90 days. Participants can also join via dial-in at +1 (800) 715-9871 (U.S./Canada toll-free) or +1 (646) 307-1963 (international) using conference ID 9788564.
Prothena (NASDAQ:PRTA), un'azienda biotecnologica in fase avanzata focalizzata sull'expertise nella disregolazione delle proteine, ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 20 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda ospiterà una conferenza audio in diretta alle 16:30 ET nello stesso giorno.
La conferenza sarà accessibile tramite il sito web dell'azienda all'indirizzo www.prothena.com nella sezione Investitori, con una registrazione disponibile per almeno 90 giorni. I partecipanti possono anche unirsi tramite il numero +1 (800) 715-9871 (numero verde USA/Canada) o +1 (646) 307-1963 (internazionale) utilizzando l'ID conferenza 9788564.
Prothena (NASDAQ:PRTA), una empresa biotecnológica en fase avanzada centrada en la experiencia en la disfunción proteica, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para jueves, 20 de febrero de 2025, después del cierre del mercado estadounidense. La empresa llevará a cabo una conferencia telefónica en vivo a las 4:30 PM ET el mismo día.
La conferencia será accesible a través del sitio web de la empresa en www.prothena.com en la pestaña de Inversores, con una repetición disponible durante al menos 90 días. Los participantes también pueden unirse por teléfono al +1 (800) 715-9871 (número gratuito de EE. UU./Canadá) o al +1 (646) 307-1963 (internacional) utilizando el ID de conferencia 9788564.
프로세나 (NASDAQ:PRTA)는 단백질 불균형 전문성을 중심으로 하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 전체 연간 재무 결과 발표를 2025년 2월 20일 목요일 미국 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분 ET에 실시간 오디오 컨퍼런스 콜을 개최합니다.
컨퍼런스 콜은 www.prothena.com의 투자자 탭에서 회사 웹사이트를 통해 접근 가능하며, 최소 90일 동안 다시 들을 수 있습니다. 참가자는 +1 (800) 715-9871 (미국/캐나다 무료 전화) 또는 +1 (646) 307-1963 (국제)로 전화하여 컨퍼런스 ID 9788564를 사용하여 참여할 수도 있습니다.
Prothena (NASDAQ:PRTA), une entreprise de biotechnologie en phase avancée axée sur l'expertise en dysrégulation des protéines, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour jeudi 20 février 2025, après la fermeture des marchés américains. L'entreprise organisera une conférence téléphonique audio en direct à 16h30 ET le même jour.
La conférence sera accessible via le site web de l'entreprise à l'adresse www.prothena.com sous l'onglet Investisseurs, avec un replay disponible pendant au moins 90 jours. Les participants peuvent également rejoindre par téléphone au +1 (800) 715-9871 (numéro gratuit États-Unis/Canada) ou au +1 (646) 307-1963 (international) en utilisant l'ID de conférence 9788564.
Prothena (NASDAQ:PRTA), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Expertise in der Proteindysregulation konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 20. Februar 2025, nach Börsenschluss in den USA angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Live-Audiokonferenz abhalten.
Die Konferenz wird über die Website des Unternehmens unter www.prothena.com im Bereich Investoren zugänglich sein, mit einer Wiederholung, die mindestens 90 Tage verfügbar ist. Teilnehmer können auch über die Nummer +1 (800) 715-9871 (USA/Kanada gebührenfrei) oder +1 (646) 307-1963 (international) mit der Konferenz-ID 9788564 teilnehmen.
- None.
- None.
The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.
To access the call via dial-in, please dial +1 (800) 715-9871 (
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213294470/en/
Investors
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Source: Prothena Corporation plc
FAQ
When will Prothena (PRTA) release its Q4 and full year 2024 earnings?
How can investors access Prothena's (PRTA) Q4 2024 earnings call?
What time is Prothena's (PRTA) Q4 2024 earnings conference call?
How long will the replay of Prothena's (PRTA) Q4 2024 earnings call be available?
